# Phase I Clinical Study Combining L19-IL2 With SABR in Patients With Oligometastatic Solid Tumor

> **NCT02086721** · PHASE1 · COMPLETED · sponsor: **Maastricht Radiation Oncology** · enrollment: 18 (actual)

## Conditions studied

- Solid Tumour

## Interventions

- **DRUG:** L19-IL2

## Key facts

- **NCT ID:** NCT02086721
- **Lead sponsor:** Maastricht Radiation Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2017-05
- **Final completion:** 2017-05
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02086721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02086721, "Phase I Clinical Study Combining L19-IL2 With SABR in Patients With Oligometastatic Solid Tumor". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02086721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*